Kevin Hern | Vice President of Investor Relations |
Dave Ricks | Chairman and CEO |
Josh Smiley | Chief Financial Officer |
Dr. Dan Skovronsky | Chief Scientific Officer |
Anne White | President of Lilly Oncology |
Ilya Yuffa | President of Lilly Bio-Medicines |
Mike Mason | President of Lilly Diabetes |
Sara Smith | Investor Relations |
Lauren Durfy | Investor Relations |
Geoff Meacham | Bank of America |
Steve Scala | Cowen |
David Risinger | Morgan Stanley |
Terence Flynn | Goldman Sachs |
Chris Schott | JP Morgan |
Seamus Fernandez | Guggenheim |
Andrew Baum | Citi |
Gregg Gilbert | Truist Securities |
Ronny Gal | Bernstein |
Vamil Divan | Mizuho Securities |
Carter Gould | Barclays |
Kerry Holford | Berenberg |
Ladies and gentlemen, thank you for standing by, and welcome to the Lilly Q4 2020 Earnings Call. At this time, all participants are in a listen-only mode. Later, we will conduct a question-and-answer session. [Operator Instructions] And as a reminder, your conference is being recorded. I would now like to turn the conference over to our host, Vice President of Investor Relations, Mr.